Company Description

Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and Bispecific TCR molecules TCER^®. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT^® technology. Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.